Pharmaceuticals

Kerendia reduces cardiovascular mortality in patients with cardiac, renal and metabolic diseases

bexib
By bexib 0 Min Read

Results from the FINE-HEART pooled analysis of three Phase 3 clinical trials highlight the potential of finerenone in treating patients with high-risk cardiovascular disease.

You Might Also Like

As the federal government cracks down on PBMs over drug costs, big pharma companies could lose pressure

UCL launches UK’s first deep brain stimulation study in children with rare epilepsy

HCP Access Declines, but Connected Field Engagement Breaks Through: Q&A with Dan Rizzo

Advances in bispecific biologic therapies for solid tumors and hematological cancers

Adapting to the highly competitive US market

Share This Article
Previous Article Naked Capitalism Fundraiser 2024: A guide to staying sane while leaders live dangerously
Next Article Supply Chains and Protectionism – Econlib
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

IMTEX, Tooltech & Digital Manufacturing 2025
Manufacturing
“Your money or your life” is defined by Google
Retail & E-commerce
Easy-to-understand English guide to Shopify Liquid
Retail & E-commerce
Singapore’s EKYC: All the ultimate guides you need to know
Fintech